# Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct05304481/  
OnCo record `nct05304481` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ATL administration in hepatocellular carcinoma, run by Lukas Biomedical Inc., now recruiting.

## Summary

Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT05304481 by Lukas Biomedical Inc., with 95 participants planned, started 2022-05-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: ATL administration.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05304481
- Phase: 2
- Setting: A Phase II Study to Evaluate the Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (HCC) Patients After Curative Treatment
- Sponsor: Lukas Biomedical Inc.
- Enrolled: 95

## Sources

- ClinicalTrials.gov NCT05304481: https://clinicaltrials.gov/study/NCT05304481

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)

---
JSON: https://onco.cc/api/v1/entities/nct05304481.json